论文部分内容阅读
抗D一般用于预防新生儿溶血病。最近一些ITP患者接受抗D治疗引起有争议的结果。有报告用2500IU抗D成功地治疗1例ITP;然而,另有报告使用抗D治疗ITP的剂量则大得多,两例患者接受的剂量分别为98000IU和88500IU。在苏格兰,一个被免疫的供者年平均提供约70万单位抗D,作者认为仅此就难以允许其在治疗ITP中大量使用。因而作者同意未经预测便不加选择地使用抗D,其效果亦无法证实的观点。过去曾积极地研究过免疫球蛋白在ITP治疗中的作用,但其作用的机理远未清晰。用免疫球蛋白治疗ITP几乎仍凭经验。血浆输注成功地用于治疗急性ITP;肌注抗疱疹病毒免疫球蛋白曾使1例ITP
Anti-D is generally used to prevent neonatal hemolytic disease. Some recent ITP patients receiving anti-D treatment have controversial results. One case of ITP was reported to be successfully treated with 2500 IU anti-D; however, another report that the dose of anti-D for the treatment of ITP was much larger was reported, with the two patients receiving doses of 98000 IU and 88500 IU, respectively. In Scotland, an immunized donor provides an average of about 700,000 units of anti-D per year, arguing that it is difficult for this alone to allow its extensive use in the treatment of ITP. Therefore, the author agrees that the unselected use of anti-D without predicting its effect will not be validated. In the past have actively studied the role of immunoglobulin in ITP treatment, but its mechanism of action is far from clear. Treatment of ITP with immunoglobulin is almost always based on experience. Plasma transfusion was successfully used in the treatment of acute ITP; intramuscular anti-herpes virus immunoglobulin once caused 1 case of ITP